For patients with IIH, sustainable weight loss offers the most effective and lasting relief from symptoms—and can help ...

Pseudoportomesenteric hypertension (PPMH) is a rare form of non-cirrhotic portal hypertension caused by increased pressure in the portal and mesenteric venous systems. Unlike traditional portal ...

New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

These disorders should be suspected in young patients with a familyhistory of hypertension who present with severe or refractory hypertension and characteristic hormonal and biochemical abnormalities.

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Hypertension (HTN) increases the risk of heart failure (HF) and it precedes it in 75 percent of cases. This article reviews essential HTN treatment in patients at risk for developing HF.

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma. MONDAY, June 23, 2024 (HealthDay News ...